About Silvergate Pharma
Silvergate Pharma is a Healthcare company based in Greenwood Village (United States) founded in 2010, and was acquired by Azurity Pharmaceuticals in June 2019. Pharmaceutical products for pediatric patients are manufactured by the company. Silvergate Pharma has raised $30.75 million across 4 funding rounds from investors including Frazier Healthcare Partners and Azurity Pharmaceuticals. Its chief executive, as recorded, is Frank Segrave. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Drugs and Diversified. Its competitors include Portola Pharma, MyoKardia and Cellino; 3 of its 3 listed competitors have raised funding.
Company details
Silvergate Pharmaceuticals was founded in 2010 and is based in Greenwood Village, United States. Operations focus on the pharmaceutical sector, with manufacturing centered on products for pediatric patients. A single product, Epaned, is currently available for treating high blood pressure in adults and children over one month old, symptomatic heart failure, and asymptomatic left ventricular dysfunction to reduce overt heart failure development and hospitalizations.
- Headquarters Greenwood Village, United States
- Stage Acquired
- SectorsHealthcare
- Website silvergatepharma.com
- Social LinkedIn
- Acquired by Azurity Pharmaceuticals (Jun 2019)
- Total Equity Funding$30.75M (USD)
in 4 rounds
- Latest Funding Round$4.6M (USD), Series B
Oct 2016
- InvestorsFrazier Healthcare Partners
& 1 more
- Acquired byAzurity Pharmaceuticals
(Jun 2019)
Funding Insights of Silvergate Pharma
Silvergate Pharma has successfully raised a total of $30.75M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $4.6 million completed in October 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $30.75M
- Total Rounds 4
- Last Round Series B — $4.6M
- First Round $23.55M
(Jun 2013)
- Investors Count 1
All 4 funding rounds of Silvergate Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2016 | $4.6M | Series B | – | – | – |
| Oct 2015 | $1.6M | Series B | – | – | – |
| Sep 2014 | $1M | Series B | – | – | – |
| Jun 2013 | $23.55M | Series B | – | Frazier Healthcare Partners | – |
2 investors in total: 2 institutional.
Investors in Silvergate Pharma
Silvergate Pharma has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Frazier Healthcare Partners and Azurity Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Generic drugs are manufactured by Azurity Pharmaceuticals in the US. | 1999 | azurity.com | Woburn, United States |
Investor details for Silvergate Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Silvergate Pharma
142 people are tracked at Silvergate Pharma (57 in leadership, 6 in board & advisors, 79 in team).
| Name | Role | Group |
|---|---|---|
Frank Segrave | CEO & President | Leadership |
Amit Lamba | Director, New Product Planning And Alliance Management | Leadership |
Robert D. | Sr. Director Of IT Operations And Cyber Security | Leadership |
Phillip Shilling Csm, Sp | Chief Of Staff | Leadership |
Jason Hatley | Vice President Human Resources | Leadership |
Eric Burge | Director Of Technical Operations | Leadership |
Sharilynne Cline | Vice President, Corporate Development | Leadership |
Dharmi Tailor | Vp, General Counsel, North America | Leadership |
Raghav Chari | Chief Business And Innovation Officer | Leadership |
Ajay Singh | Chief Scientific Officer | Leadership |
Brian Wojick | Chief Digital & Information Officer | Leadership |
Darren Byrne Fca | Vice President, Finance Namr, Europe And International | Leadership |
Jordan Hunter | Vice President, Strategic Finance & Enablement | Leadership |
Lauren Whitehead | Chief Financial Officer | Leadership |
Paul Murasko | Head Of Digital Innovation Marketing Operations | Leadership |
Ronald L. Scarboro | CEO | Leadership |
Hanok George | Chief Legal, Compliance & HR Officer | Leadership |
Sheila Bhattacharya | Vp, Market Access And Strategic Accounts | Leadership |
Terrence Terifay | Chief Commercial Officer | Leadership |
Suresh Marella | Head Of IT India, Global Infra & Operations | Leadership |
122 more people are available in the full profile.
Complete people profiles for Silvergate Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Silvergate Pharma
4 dated milestones of Silvergate Pharma across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Silvergate Pharma is founded.
- Funding First funding round of $23.6M.
- Funding Latest funding round, Series B, of $4.6M.
- Exit Acquired by Azurity Pharmaceuticals.
Competitors of Silvergate Pharma
Silvergate Pharma has 3 listed competitors in our database, 3 of them funded. They include Portola Pharma, MyoKardia and Cellino.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| portola.com | 2003 | San Francisco, United States | $296.09M | 369 | Therapeutics for cardiovascular and autoimmune diseases are developed. | |
| myokardia.com | 2012 | San Francisco, United States | $98M | 224 | Specialized drugs are developed for genetic heart diseases. | |
| cellinobio.com | 2017 | Cambridge, United States | $125M | 63 | Developer of autologous cell therapies |
Detailed competitors of Silvergate Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as Silvergate Pharma (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Silvergate Pharma
Complete news archive for Silvergate Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Silvergate Pharma
Silvergate Pharma was founded in 2010 and raised its 1st funding round 3 years after it was founded.
Silvergate Pharma is headquartered in Greenwood Village, United States. It is registered at Greenwood Village, Colorado, United States.
Frank Segrave is the CEO of Silvergate Pharma, as recorded in our data.
Silvergate Pharma is a funded company, having raised a total of $30.75M across 4 funding rounds to date. The company's 1st funding round was a Series B of $23.55M, raised on Jun 2013.
Silvergate Pharmaceuticals was founded in 2010 and is based in Greenwood Village, United States. Operations focus on the pharmaceutical sector, with manufacturing centered on products for pediatric patients. A single product, Epaned, is currently available for treating high blood pressure in adults and children over one month old, symptomatic heart failure, and asymptomatic left ventricular dysfunction to reduce overt heart failure development and hospitalizations.
Silvergate Pharma's top competitors include Cellino, MyoKardia and Portola Pharma.
Silvergate Pharma has 2 investors. Key investors include Frazier Healthcare Partners, and Azurity Pharmaceuticals.
Yes. Silvergate Pharma was acquired by Azurity Pharmaceuticals in June 2019.